John W. Eikelboom
McMaster University
CardiologyAtrial fibrillationStrokeDiabetes mellitusMedicine
What is this?
Publications 756
#1Tim A. C. de Vries (UvA: University of Amsterdam)
#2Jack Hirsh (McMaster University)H-Index: 130
Last. Noel C. Chan (McMaster University)H-Index: 13
view all 9 authors...
BACKGROUND Recent reports suggest an important contribution from frequent off-label use of apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in observational studies (OSs) relative to in randomized controlled trials (RCTs), and consequently, advocate against such use in all patients. OBJECTIVES To examine factors contributing to the higher thromboembolic event rates, we estimated the prevalence of off-label use in contemporary practice, and compared patient charac...
Ty J. Gluckman, MD, FACC, Chair Niti R. Aggarwal, MD, FACC Nicole M. Bhave, MD, FACC Gregory J. Dehmer, MD, MACC Olivia N. Gilbert, MD, MSc, FACC Chayakrit Krittanawong, MD Dharam J. Kumbhani, MD, SM, FACC Javier A. Sala-Mercado, MD, PhD Andrea L. Price, CPHQ, RCIS, AACC David E.
#1Luciana Catanese (Population Health Research Institute)H-Index: 6
#2John W. Eikelboom (Population Health Research Institute)H-Index: 92
Last. Robert G. Hart (Population Health Research Institute)H-Index: 92
view all 10 authors...
Objective Subdural hematomas (SDHs) are an uncommon, but important, complication of anticoagulation therapy. We hypothesized that the risks of SDH would be similar during treatment with oral factor Xa inhibitors compared with aspirin. Methods We assessed the frequency and the effects of antithrombotic treatments on SDHs in the recent international Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial comparing aspirin 100 mg daily, rivaroxaban 5 mg twice ...
#1Matt Wheeler (McMaster University)
#2Noel C. Chan (McMaster University)H-Index: 13
Last. John W. Eikelboom (McMaster University)H-Index: 92
view all 3 authors...
In the COMPASS trial, the combination of rivaroxaban 2.5 mg twice daily and low-dose aspirin 75-100 mg daily produced a net clinical benefit of 20% in patients with chronic atherosclerotic vascular disease because it reduced major adverse events by 24% and overall mortality by 18% despite an initial increase in major bleeding. In this paper, we examine the rationale for targeting coagulation factor Xa in patients with atherosclerosis, summarize the pharmacology of the 2.5-mg dose, review the tri...
#1Subodh Verma (U of T: University of Toronto)H-Index: 42
#2John W. Eikelboom (McMaster University)H-Index: 92
Last. Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 128
view all 7 authors...
Inhibiting thrombosis is a cornerstone of vascular protection. Antiplatelet therapies, like aspirin and P2Y12 inhibitors, are used to prevent thrombosis and are widely endorsed in current clinical practice recommendations. Recent data suggest that “dual anti-thrombotic pathway inhibition” targeting platelets and coagulation may further reduce the residual atherosclerotic risk. This innovative thesis was tested in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) t...
#1John W. Eikelboom (Population Health Research Institute)H-Index: 92
#2Alexander P. Benz (Population Health Research Institute)H-Index: 1
#1Kamilla Steensig (Aarhus University Hospital)H-Index: 2
#2Kevin Kris Warnakula Olesen (Aarhus University Hospital)H-Index: 7
Last. John W. Eikelboom (McMaster University)H-Index: 92
view all 11 authors...
ABSTRACT Patients without atrial fibrillation (AF) constitute approximately 75% of patients suffering thromboembolism and major adverse cardiovascular events (MACE), but evidence supporting risk stratification in these patients is sparse. We aimed to develop a risk prediction model for identification of patients without AF at high risk of first-time thromboembolic events. We included 72,381 coronary angiography patients without AF and without prior ischemic stroke or transient ischemic attack. T...
#1Krishnan Shyamkumar (Population Health Research Institute)
#2Jack Hirsh (McMaster University)H-Index: 130
Last. Noel C. Chan (McMaster University)H-Index: 13
view all 9 authors...
Until recently, attempts to improve the benefit of aspirin by adding another antithrombotic agent have not resulted in a mortality reduction in patients with chronic symptomatic atherosclerosis. In this population, COMPASS is the only one among six trials to show a significant mortality reduction, thereby providing evidence of a clear net clinical benefit with the combination of low-dose rivaroxaban plus aspirin. In this systematic review, we sought to determine whether the mortality benefit of ...
#1Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 128
#2John W. Eikelboom (Population Health Research Institute)H-Index: 92
Last. Olga Shestakovska (Population Health Research Institute)H-Index: 15
view all 20 authors...
Background: Patients with established coronary artery disease (CAD) or peripheral artery disease (PAD) often have diabetes mellitus. These patients are at high risk of future vascular events. Metho...
4 CitationsSource
#1Behnood Bikdeli (Yale University)H-Index: 16
#2Mahesh V. Madhavan (NewYork–Presbyterian Hospital)H-Index: 4
Last. Elissa Driggin (NewYork–Presbyterian Hospital)H-Index: 3
view all 54 authors...
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithromb...
5 CitationsSource